Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment
- 1 January 2022
- journal article
- review article
- Published by Elsevier in Pharmacological Research
- Vol. 175, 105997
Abstract
No abstract availableKeywords
This publication has 144 references indexed in Scilit:
- The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α productionJournal of Translational Medicine, 2013
- Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II StudyJournal of Clinical Oncology, 2012
- Basis of CTLA-4 function in regulatory and conventional CD4+ T cellsBlood, 2012
- Constitutive Clathrin-mediated Endocytosis of CTLA-4 Persists during T Cell ActivationJournal of Biological Chemistry, 2012
- Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4Science, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodiesJournal of Experimental Medicine, 2009
- Sequence, structure, function, immunity: structural genomics of costimulationImmunological Reviews, 2009
- CTLA-4 Activation of Phosphatidylinositol 3-Kinase (PI 3-K) and Protein Kinase B (PKB/AKT) Sustains T-Cell Anergy without Cell DeathPLOS ONE, 2008
- Cytotoxic T lymphocyte antigen‐4‐dependent down‐modulation of costimulatory molecules on dendritic cells in CD4+ CD25+ regulatory T‐cell‐mediated suppressionImmunology, 2006